Smith & Nephew plc Rating Reiterated by Morgan Stanley (SN)
Smith & Nephew plc (LON:SN)‘s stock had its “overweight” rating reaffirmed by Morgan Stanley in a research note issued on Monday, Stock Ratings Network.com reports. They currently have a GBX 988 ($16.60) price target on the stock. Morgan Stanley’s target price points to a potential upside of 7.98% from the stock’s previous close.
Smith & Nephew plc (LON:SN) opened at 924.50 on Monday. Smith & Nephew plc has a one year low of GBX 720.00 and a one year high of GBX 964.0001. The stock has a 50-day moving average of GBX 906.9 and a 200-day moving average of GBX 866.3. The company’s market cap is £8.250 billion.
Several other analysts have also recently commented on the stock. Analysts at Investec reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Monday. They now have a GBX 1,100 ($18.48) price target on the stock. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note on Friday. They now have a GBX 865 ($14.53) price target on the stock. Finally, analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Friday. They now have a GBX 1,000 ($16.80) price target on the stock. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of GBX 921.33 ($15.48).
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.